Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection.
about
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activitiesImpact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy.Immune activation, CD4+ T cell counts, and viremia exhibit oscillatory patterns over time in patients with highly resistant HIV infectionModeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching timesThe latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance.Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North AmericaEffect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations.Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.The dynamics of CD4+ T-cell depletion in HIV disease.Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.Human retroviruses after 20 years: a perspective from the past and prospects for their future control.In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1.A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan AfricaHigh prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectivenessEvolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapyEvolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failureEffective T-cell responses select human immunodeficiency virus mutants and slow disease progression.Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trialCD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.Systemic Cytokine Levels Do Not Predict CD4(+) T-Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus InfectionThe interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting.Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West AfricaMisclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settingsEvaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in IndiaHistory-adjusted marginal structural models for estimating time-varying effect modification.Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoringCCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individualsRepositioning HIV protease inhibitors as cancer therapeuticsPlasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infectionDelaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.Nine-year follow-up of HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral Therapy: a Bayesian approach.Optimal Allocation of Gold Standard Testing under Constrained Availability: Application to Assessment of HIV Treatment Failure.Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals.Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.
P2860
Q24550608-12AF60CD-4B89-433B-8386-0D84858BAE12Q25257691-0DA02E93-B846-469D-A231-380B075BA190Q28478654-147B4231-F947-434F-8A22-D3E3736AC4F5Q30655744-B167FA28-943C-45E5-A836-03A73EDAB839Q33212237-4B6646CC-1A5B-442E-AE56-082AB90ECA99Q33853922-02F77A8D-445E-4EAD-8D7D-E99295A1A14AQ33912028-19B74145-44CA-4982-9D9C-5997C6B49DA4Q33924628-3DA15246-EBF4-469C-AC25-6AA32CC6FD66Q33942992-A8A63127-7E94-4731-BAB1-9687C1F1ECA1Q33981074-9C782CD3-3370-4BE9-ADEE-0CFC1DD9B1E2Q34792498-EE68D98C-725E-4B91-8CCB-02FFCC9D02A3Q34991044-5FE3E8A9-6550-42C2-A110-99DAF580993BQ35126864-FE62553F-EF38-4DA2-824E-F97D71AA3234Q35156558-EF632812-3FC2-4EFD-BBA4-6C46733FCDA6Q35217495-1357CD53-E7C3-49F5-8841-45FE3DA3CA1FQ35264750-6D3132A3-DE2D-4B8C-8F54-E90C2FBBCAEEQ35698801-DDD0C49F-754D-493C-97C1-0924551083D9Q35857259-48595BF8-062D-4D09-B9D0-388DFF4F80E0Q36011358-27C50BB7-0BCA-4FA6-A0F7-89D78E034F73Q36132255-F8D0ED57-E467-43AD-8F8A-45E49C046344Q36179320-3D29AD7D-5C4C-42E1-A343-FE2B803D677FQ36180809-C14BF4DC-3628-49E1-A533-561BB5729A0EQ36555263-BE0797E1-0D61-42FA-B02F-F5FC75B6BB78Q36661588-64176B33-BDEB-414B-B857-53441E79C7B1Q36763062-A60FA373-418B-4555-99D6-679E491FEF1FQ36793768-121797B9-B865-4262-A9B1-651D895DE1A7Q36877987-6E80F8EC-2830-4AE6-8B72-F0523D489DBAQ36902291-A09549D8-1458-43AE-B373-10228107868CQ36924003-9E33CD7C-0658-410C-B561-EC5A59329300Q36933327-AC96E827-24E7-44A0-8E75-7B119AF36D13Q37072697-83E1B5E5-6EE3-44E8-9129-A19D3D3C0A6BQ37192579-F1B5170D-6B61-4B0C-A595-9537036F6A83Q37309633-CDD5E70D-74E3-4927-9E04-EA7F7FEA4239Q37371248-CAB28EDA-304F-4EDD-98F5-8562AAD311C7Q37441637-CA68406F-337A-4897-A05C-CA83EF3C669CQ37504245-809DAB98-9D86-4D59-B3EA-0F40EFDDBF60Q37567887-FC58D4B4-CA8A-41A7-9C0E-CA87CA5524AFQ37658177-96FF98C6-5689-447F-B161-49483DE832EDQ37713470-52F9DCFA-3C94-4CC0-A46A-F6A2712929C2Q38449098-F8FDD527-9FFD-4ECC-91F4-D8DAEFF84127
P2860
Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Sustained CD4+ T cell response ...... unodeficiency virus infection.
@en
type
label
Sustained CD4+ T cell response ...... unodeficiency virus infection.
@en
prefLabel
Sustained CD4+ T cell response ...... unodeficiency virus infection.
@en
P2093
P356
P1476
Sustained CD4+ T cell response ...... unodeficiency virus infection.
@en
P2093
P304
P356
10.1086/315334
P407
P577
2000-03-01T00:00:00Z